Elevance Health Medicaid Securities Fraud Lawsuit
Analysis based on 27 articles · First reported May 13, 2025 · Last updated Jun 22, 2025
The lawsuit against Elevance Health for alleged securities fraud, stemming from misrepresentations about United States — Medicaid cost trends, has led to significant declines in Elevance Health's stock price. This event highlights the financial risks associated with companies involved in government healthcare programs and the importance of accurate financial reporting, potentially impacting investor confidence in the health insurance sector.
A securities fraud class action lawsuit has been filed against Elevance Health and its senior executives by Bleichmar Fonti & Auld LLP. The lawsuit, pending in the United States — United States District Court for the Southern District of Indiana, alleges that Elevance Health made misleading statements regarding the cost trends and utilization of its United States — Medicaid members following the end of the COVID-19 federal pause on eligibility redeterminations in 2023. Elevance Health allegedly failed to reflect the increased acuity and utilization of its United States — Medicaid members in its rate negotiations and 2024 financial guidance. This alleged misrepresentation led to significant stock price declines for Elevance Health on July 17, 2024 (nearly 6%) and October 17, 2024 (nearly 11%) after the company revealed increased United States — Medicaid utilization and missed Q3 2024 earnings expectations due to elevated medical costs. Investors have until July 11, 2025, to seek appointment as lead plaintiff in the case.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard